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Cervical cancer is a major health problem among 
women worldwide with developing countries con-
tributing 85% of all cases [1, 2]. India also reflects 
a similar picture as cancer cervix is the second most 
common cancer in women in India with high prev-
alence in rural areas [3]. Due to the inadequacy of 
population-based screening programs, lesser ac-
cess to proper healthcare facilities in rural areas, 
lack of health education and awareness, especially 
among the high-risk groups, 70–80% cases of cervi-
cal cancer present in advanced stages (stage III and 
IV) in India [4]. Along with the local extent of dis-
ease, nodal status also greatly influences the treat-
ment strategy and outcome. Probability of lymph 
node involvement increases as the clinical stage 
advances. Nelson et al. showed that the incidence 
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background: cervical cancer is a major health problem, especially in developing countries like India. extended field radio-
therapy (eFrT) for cancer cervix treatment remains a challenging task for radiation oncologists. In the last decade studies have 
shown that eFrT using intensity modulated radiotherapy (IMrT) is feasible in treating gynaecological malignancies but there 
is a dearth of literature on this specific topic from this part of the world where patient profile differs greatly in several aspects 
from that of the western world. The aim of the study was evaluation of treatment response and toxicity profile in cases of 
carcinoma cervix with metastatic para-aortic nodes treated with intensity modulated radiotherapy technique.
Materials and methods: In this retrospective study the treatment records of 45 para-aortic node positive cervical cancer 
patients treated with eFrT (IMrT) and concurrent cisplatin were analysed for evaluation of loco-regional control and toxicities.
results: Forty-four patients received full course of treatment. among those 44 patients, 93.2% achieved complete response. 
Overall, the treatment was tolerated well and toxicities were within acceptable limits. acute grade 3–4 toxicities were observed 
mostly in the form of anaemia and leucopenia. Most common late toxicities were those of small and large intestine.
conclusion: eFrT with concurrent chemotherapy was successfully delivered for para-aortic nodes positive cervical cancer 
patients in Indian scenario where under-nutrition, infection, anaemia and several other factors adversely influence treatment 
outcome. pelvic and para-aortic control rates were satisfactory. The technique was associated with an acceptable acute and 
late toxicity profile.
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of metastasis to para-aortic lymph nodes (PALN) 
in stage IIB cancer cervix was 16% ,whereas in stage 
IIIB it was as high as 46% [5]. Para-aortic lymph 
node metastasis itself is a poor prognostic factor for 
cervical cancer. Moreover, when these patients are 
treated with External Beam Radiotherapy (EBRT) 
up to the PALN level, the total irradiated volume 
and dose to the organs at risk increase significantly 
compared to pelvis only irradiation, resulting in 
added morbidity and making it a challenging task 
for the radiation oncologists.
In RTOG 79-20 trial (1995), it was shown that 
extended field radiotherapy (EFRT) improved 
overall survival (OS) in cervical cancer compared 
to standard pelvis only irradiation (55% vs. 44%, 
p = .02) but grade 4 and 5 toxicities were signifi-
cantly higher in the EFRT arm as compared to the 
pelvis only arm (8% vs. 4%). Locoregional control 
rate was similar in both arms [6]. Many other stud-
ies also reported more or less similar results [7, 8] 
and, consequently, till date prophylactic para-aortic 
nodal irradiation (EFRT) is not a standard recom-
mendation. On the other hand, few other studies 
showed that patients with documented spread to 
PALN can potentially become long-term survivors 
following locoregional radiotherapy [9, 10]. As 
a result, EFRT has become a standard of care for 
cervical cancer patients with documented PALN 
involvement, whenever feasible, after careful assess-
ment of risk and benefit. Goodman et al. compiled 
survival statistics on cervical cancer patients with 
para-aortic lymph node metastasis and found an 
average 5-year survival rate of approximately 40% 
when treated with EFRT alone or EFRT plus che-
motherapy [11].
In 1999, the National Cancer Institute (NCI) of 
the United States of America recommended cis-
platin based chemotherapy concurrent with radia-
tion, as the standard treatment protocol for cervical 
cancer patients, who require radiation. All of those 
trials [12–16], based on which the NCI recommen-
dation was established, excluded patients with pa-
ra-aortic lymph node metastasis. So, based on these 
trials, no logical conclusion could be drawn about 
the effectiveness of concurrent chemo-radiotherapy 
(CCRT) in improving the survival of patients with 
para-aortic node metastasis.
In the pre-Intensity Modulated Radiotherapy 
(IMRT) era, several large trials have been con-
ducted to assess treatment response and toxicity in 
cervical cancer patients with metastatic para-aortic 
lymph node treated with EFRT, using four field 
box or opposed anterior-posterior beam and con-
current chemotherapy followed by brachytherapy. 
In those trials, the dose of external beam radio-
therapy (EBRT) to PALN ranged from 45–50.4 Gy 
with subsequent boost (in some trials) to involved 
nodes up to 54–59 Gy. Although, the survival rates 
were about 30–40%, the incidences of acute grade 
3/4 toxicities (20–80%) and late severe toxicities 
(7–20%) were quite high in these studies [17–21].
Since the first decade of the twenty-first century, 
the feasibility of IMRT is being explored in the 
treatment of cervical cancer with the hope of im-
proved tumour control and lesser radiotherapy as-
sociated toxicity. In a survey in 2002, 15% of IMRT 
users reported treating a gynaecology patient with 
this technique [22]. In the follow-up survey in 2004, 
this percentage increased to 35% [23]. That data 
itself was a statement about the impact of IMRT in 
the treatment of gynecologic cancers.
The role of EF-IMRT for advanced cervical can-
cer was also being evaluated during that time with 
an aim to limit the treatment-related toxicities in 
various centres with promising results. In a dosi-
metric study of extended-field IMRT (EF-IMRT), 
Portelance et al. [24] showed better normal tissue 
sparing without changes in the target coverage. 
Gerszten et al. [25] conducted a study with 22 pa-
tients (2 having PALN metastasis) and concluded 
that EFRT using IMRT was quite feasible in treating 
gynecologic malignancies as did Salama et al. [26] 
with their experience of treating 13 such cases.
Beriwal et al. [27] conducted a similar study to 
assess early clinical outcomes with concurrent cis-
platin and EF-IMRT for carcinoma of the cervix 
with 36 patients including 10 having positive PALN. 
The treatment was tolerated well with a good lo-
co-regional control rate (34 patients achieved com-
plete response), with distant metastases being the 
predominant mode of failure (2 infield recurrence 
and 9 distant metastases).
An electronic search of the PubMed database 
was performed to obtain key literature on this topic 
but only a few were found from this part of the 
world [28]. Like most other developing countries, 
India also has relatively few public cancer hospitals 
with IMRT facilities at present, with our centre be-
ing one of them, and which have used IMRT in this 
setting.  Hence, the assessment of feasibility and 
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efficacy of IMRT in the treatment of PALN positive 
cervical cancer in the Indian scenario was taken up 
for investigation in this retrospective study with 
the primary objective of evaluating locoregional 
control and toxicity (acute and late).
Materials and methods
This was a retrospective observational study con-
ducted at a tertiary cancer hospital in India. The 
treatment records of 45 para-aortic node positive, 
histopathologically proven cervical cancer patients 
aged between 20–65 years with Karnofsky Perfor-
mance Score ≥ 60, normal hemogram and bio-
chemical profiles at baseline and treated with EFRT 
plus weekly concurrent cisplatin during the period 
of June 2012 to June 2015, were analysed from the 
hospital database. Nodal status was assessed by 
CT-Scan only (as the institute lacked a PET-CT 
Scan facility). No surgical assessment of nodes was 
done and patients having nodes larger than 3 cm 
were excluded from the study. Due approval of the 
institutional ethics committee was taken before 
analysing the data.
The prescribed dose of external beam radio-
therapy (EBRT) was 50.4 Gy in 28 fractions to the 
Planning Target Volume (PTV) along with weekly 
cisplatin (40 mg/m2). No nodal boost was given as 
the optimal dose for acceptable toxicities is not well 
established in the Indian patient population. Dose 
constraints to organs at risk were prescribed as fol-
lows: kidney — mean dose < 15–18 Gy, spinal cord 
— Dmax < 50 Gy, bowel bag — V 45 < 195 cc, liver 
mean dose < 30 Gy, femoral head — V 50 < 5%. 
All patients were planned to receive 4 fractions of 
weekly intracavitary High Dose Rate (HDR) Ir192 
Brachytherapy starting from the 4th week of EBRT. 
Dose per fraction of HDR intracavitary brachyther-
apy was 6 Gy calculated at the conventional point 
A as per our institutional practice. All patients were 
reviewed meticulously for assessment of any radia-
tion reaction or chemotherapy related toxicity dur-
ing the whole course of treatment.
CT-simulation for all patients was done with 
a full bladder protocol and in a supine position.
Nodal contouring: Clinical target volume for 
lymph nodes (CTV-N) included para-aortic, com-
mon iliac, external iliac, internal iliac, obturator 
and presacral lymph nodes. Para-aortic nodal 
contouring was started at the level of celiac trunk. 
Involved nodes were contoured as nodal gross tu-
mour volume (GTV-N) and 1 cm margin was given 
around GTV-N to draw CTV-N. Uniformly, blood 
vessels were given a margin of 7 mm to draw the 
nodal CTV for pelvic nodes. The contour was ex-
tended around common iliac vessels posteriorly 
and laterally so as to include connective tissue be-
tween iliopsoas muscles and lateral surface of the 
vertebral body.
Contouring of different volumes for the primary 
tumour: CTV Primary (CTV-P) included GTV Pri-
mary, uterine cervix, uterine corpus, parametrium, 
vagina and ovaries. For the vagina, paravaginal tis-
sue was included along with the vaginal wall. The 
lower extent of disease was marked with a fiducial 
marker during CT-simulation and CTV-P was con-
toured up to 2 cm below this marker. For parame-
trium, the cranial border was defined at the level 
where the true pelvis began. Superiorly, contouring 
was stopped once loops of bowel were seen next to 
the uterus. Anteriorly, delineation was done up to 
the posterior border of the bladder in the central 
region, while, in the periphery, it extended up to 
the anterior end of the lateral pelvic bony wall. 
Posteriorly, the parametrium was contoured only 
up to the anterior part of the mesorectal fascia. In 
the case of significant parametrial invasion (stage 
IIIB) or uterosacral ligament involvement, the en-
tire mesorectum was included in CTV-P. Laterally, 
the parametrium was contoured up to the medial 
edge of internal obturator muscle. Caudal border 
of the parametrium was taken at the medial border 
of the levatorani or at the pelvic floor.
Planning target volume (PTV) margin: the uter-
ine motion was accounted for by giving an asym-
metric PTV margin over CTV-P, with 15 mm an-
tero-posteriorly, 15 mm supero-inferiorly and 10 
mm laterally. All plans were done by using 7 to 9 
coplanar beams (6 MV photons). Collimator angle 
of 45 degrees was given for better coverage (Fig. 1).
Patient’s position was verified with cone-beam 
computed tomography (CBCT) during the course 
of treatment to check the reproducibility of patient 
set-up.
statistical analysis
Descriptive statistical analyses were performed 
to calculate the means with corresponding stan-
dard deviations (SD). Test of proportion was 
used to find the standard normal deviate (Z) and 
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Chi-square χ2 test was performed to find the as-
sociations. P ≤ 0.05 was taken to be statistically 
significant. Kaplan-Meier survival analysis and 
Log Rank test were performed to assess the over-
all survival/disease-free survival and to compare 
the same between two independent groups, re-
spectively.
Follow up: At 1 month after completion of the 
full course of treatment, all the patients had their 
first evaluation to assess the treatment response 
clinically and by CT-Scan of the abdomen and 
pelvis. The response was assessed using response 
evaluation criteria in solid tumours (RECIST ver-
sion 1.1) [29]. Thereafter, the clinical follow up con-
tinued every 3 months for the first year and then 
at 6-month intervals. Appropriate investigations, 
including imaging (CT-Scan/MRI/ PET-CT Scan) 
and definitive histopathological assessment, were 
done in suspected cases of recurrent tumour as 




The mean age (mean ± SD) of the patients was 
52.93 ± 5.80 years with the range of 38–64 years. Base-
line patients’ characteristics are given below in Table 1. 
Treatment response
Forty-four (44) patients received the full course 
of radiotherapy except for one patient who did not 
receive the last fraction of intracavitary brachyther-
apy as she had persistent central disease with pelvic 
nodes during that time and developed a systemic 
infection and renal failure subsequently. Thirty-five 
table 1. Baseline patients’ characteristic
Age (Years) 35–44 45–54 55–64 Total
Number 2 22 21 45
Clinical Stage II B III B
Number 13 32 45
Histology squamous cell carcinoma adenocarcinoma
Number 43 2 45
Co-morbidities DM hTN IhD NIL
Number 5 6 1 33 45
KPS 70 80 90
Number 2 17 26 45
DM — diabetes mellitus; hTN — hypertension; IhD — ischemic heart disease
Figure 1. Beam arrangement and dose painting (from treatment planning system)
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patients (77.8%) received all 6 cycles of chemother-
apy (weekly cisplatin 40 mg/m2), whereas 5 cycles 
and 4 cycles of chemotherapy were received by 4 
and 6 patients, respectively. Leucopenia, anaemia, 
nausea and vomiting were the main reasons for 
discontinuation of chemotherapy.
Among those 44 patients who completed radio-
therapy, 41 patients (93.2%) achieved complete re-
sponse. Two among the remaining three patients 
who showed partial response had persistent pa-
ra-aortic node (one of them with pulmonary me-
tastases) and the other one had both pelvic and 
para-aortic nodes. So, para-aortic nodal control 
was 93.2%, which was a satisfactory outcome.
The duration of median follow up was 26 months 
(range 2-41 months). Mean and 2-year disease 
free survival (DFS) were 21.19 ± 9.91 months and 
51.16%, respectively (Fig. 2). The log-rank test 
showed that there was no significant difference in 
the disease-free survival pattern of clinical stage 
IIB and stage IIIB patients (p > 0.05). Twelve (12) 
patients (29.27%) presented with recurrent disease 
within the irradiated field or distant metastases 
during the subsequent course of follow-up. Among 
those 12 patients, 3 patients (7.32%) had central 
disease recurrence (2 in the cervix, 1 in the anterior 
wall of the rectum); 2 patients (4.87%) had recur-
rent para-aortic nodes; 3 had a recurrence in the 
pelvic nodes (among those one had vertebral me-
tastases) and 4 patients (9.76%) developed isolated 
distant metastases outside the irradiated field. 
Mean and 2-year overall survival (OS) were 
24.44 ± 9.21 months and 67.44%, respectively, and 
there was no significant difference in the overall 
survival pattern of clinical stage IIB and stage IIIB 
patients (p > 0.05) (Fig. 3).
Toxicity profile
Overall, the whole course of treatment was 
tolerated well by most of the patients. Toxicities 
observed during treatment and within the first 3 
months of completion of treatment were consid-
ered as an acute toxicity and beyond that as late 
toxicity. 
Acute grade 3 or grade 4 toxicities were observed 
mostly in the form of anaemia and leucopenia. Both 
grade 3 anaemia and leucopenia were seen in 10 pa-
tients (22.2%) and only one patient suffered from 
grade 4 leucopenia. Two (2) patients (4.4%) had 
incidence of acute grade 3 skin reaction, whereas 
the incidence of acute grade 3 toxicity for upper GI, 
lower GI and pelvis, and the genitourinary system 
was minimal (2.2%) (Tab. 2).
Thirty-two (32) patients (72.73%) completed the 
overall treatment within 8 weeks duration. Twenty 
(20) patients (44.4%) needed treatment break, but 
among those only 3 patients (15%) suffered treat-
ment interruption of more than 7 days. Haemato-
logical toxicities followed by nausea and vomiting 
were the most common causes of treatment inter-
ruption.
Till the date of the last follow-up, most common 
late toxicities were those of the small and large in-
testine followed by the urinary bladder. Incidences 
of grade 3 or grade 4 late toxicities were observed in 
4 patients (9.1%). Two (2) patients suffered grade 4 



















































Figure 2. Disease free survival curve
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bowel toxicity (1 fistula and 1 sub-acute intestinal 
obstruction), one (1) patient showed the features of 
grade 3 bowel toxicity and one had grade 3 bladder 
toxicity (Tab. 3).
Discussion
While the potential for normal-tissue sparing is 
the main motivation behind the implementation 
of IMRT for cervical cancer, achieving good target 
coverage remains the primary objective. Consistent 
and accurate target volume definition as per avail-
able guidelines was essential as the salvage treat-
ment for relapsed disease due to a geographic miss 
is rarely successful [30]. The target volumes con-
toured in the pelvis were generous, accounting for 
the inability to clearly delineate the areas at risk by 
CT criteria. The volumes closely approximated the 
large pelvic fields traditionally used to treat cervi-
cal cancer but the extended field portion, covering 
the para-aortic nodes, was less generous. As the 
PTV margins were relatively tight, the help of im-
age guidance during the delivery of radiotherapy 
was taken.
We prescribed 50.4 Gy to PTV in 28 fractions 
with no simultaneous or subsequent boost to in-
volved nodes. In the pre IMRT era, several authors 
treated PALN in cervical cancer patients by conven-
tional EFRT with concurrent chemotherapy. Among 
those studies, Grisby et al. [17] (RTOG 92-01) and 
Small W Jr et al. [18] (Arm 1 of RTOG 0116) treat-
ed nodal PTV with 48 Gy and 45 Gy, respectively, 
followed by a boost to the involved nodes up to 
54–59.4 Gy. They reported very high rates of RTOG 
G3/G4 toxicities. Varia et al. [19] treated PALN with 
45 Gy and no subsequent boost to involved nodes 
and managed to achieve similar treatment outcome 
with a less severe toxicity profile.
In the IMRT era, Gerszten et al [25]. and Beriwal 
et al. [27] used the simultaneous integrated boost to 
treat the involved nodes with dose up to 55–60 Gy 
while prescription for whole nodal PTV was 45 Gy 
in 25 fractions. Both authors reported good disease 
control with an acceptable toxicity profile. 
A large proportion of our patients (44.4%) had 
suffered acute RTOG grade 2 skin toxicity which 
was a bit higher than those reported in the previ-
ously mentioned trials. The difference was most 
likely due to poor maintenance of hygiene by our 
patients and the hot and humid weather in this 
part of the world. Other acute and late toxicities 
were comparable to those reported in the western 
population.
We implemented HDR intracavitary brachyther-
apy, using 2-dimentional fluoroscopic image guid-
ance, from the fourth week of EBRT to cut short 
the overall treatment time. Most of our patients 
(55.56%) needed no treatment interruption and 32 
patients (72.73%) completed the overall treatment 
within 8 weeks. 
Although haematological toxicities were the 
most common cause of treatment interruption, the 
table 2. acute toxicity profile
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Total no. of patient
acute upper GI toxicity 15 19 10 1 0 45
acute lower GI and pelvic toxicity 5 16 23 1 0 45
anaemia (hb %) 5 11 19 10 0 45
Leucopenia 8 12 14 10 1 45
acute toxicity of skin 5 18 20 2 0 45
acute genitourinary toxicity 15 19 10 1 0 45
table 3. Late toxicity profile
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Total No. of Patient
Bladder 34 7 2 1 0 44
small/Large intestine 28 8 5 1 2 44
Kidney 41 2 1 0 0 44
skin 36 8 0 0 0 44
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overall results were quite satisfactory despite the 
relatively compromised nutritional and immune 
status of our patients. The pelvis and spine contain 
a significant volume of bone marrow tissue and 
irradiation of these regions has a known impact 
on peripheral blood counts. IMRT may also allow 
significant sparing of bone marrow. 
We could not use PET-CT scan for diagnosis, 
treatment planning or response assessment as our 
institution did not have PET-CT scan facility at 
that time and most of our patients could not af-
ford a PET-CT Scan in a private hospital. This is 
a limitation of this study but CT based assessment 
still is the major option in resource constrained 
settings.
We may consider intensifying this so far well 
tolerated treatment regimen by adding simultane-
ous/sequential boost dose to involved nodes, pref-
erably by PET-CT based planning, for any further 
improvement in loco-regional control in the future. 
conclusion
In this retrospective observational study, an 
intensity-modulated radiotherapy technique was 
used to deliver extended field radiotherapy with 
concurrent chemo-sensitization for para-aortic 
nodes-positive cervical cancer patients in the In-
dian scenario, where undernutrition, infection, 
anaemia, and several other socio-economic factors 
adversely influence successful treatment delivery 
and treatment outcome. Pelvic and para-aortic 
nodal control rates were comparable to those in 
the literature. The treatment was associated with 
an acceptable acute and late toxicity profile without 
significant treatment prolongation. The impact of 
simultaneous nodal boost (using PET-CT based 
planning) may be assessed to determine its role 
in further improving disease outcome among the 
Indian patient population. This potential role for 
IMRT merits further evaluation with larger patient 
numbers and longer follow-up, preferably with 
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